Financier looks to parlay a $5M Alzheimer’s deal into instant $172.5M IPO

Vivek Ramaswamy
Just before Christmas last year, a newly formed Bermuda-based biotech run by former hedge fund partner Vivek Ramaswamy struck a deal to in-license a shelved Alzheimer’s drug from GlaxoSmithKline ($GSK) with plans to put it into Phase III. That late-stage study won’t start until the fourth quarter, but the newborn biotech isn’t waiting around at the starting line. The […]